AU2002239229A1 - Receptor for b. anthracis toxin - Google Patents

Receptor for b. anthracis toxin

Info

Publication number
AU2002239229A1
AU2002239229A1 AU2002239229A AU3922902A AU2002239229A1 AU 2002239229 A1 AU2002239229 A1 AU 2002239229A1 AU 2002239229 A AU2002239229 A AU 2002239229A AU 3922902 A AU3922902 A AU 3922902A AU 2002239229 A1 AU2002239229 A1 AU 2002239229A1
Authority
AU
Australia
Prior art keywords
anthrax toxin
polypeptides
present
polynucleotides
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002239229A
Inventor
Kenneth A. Bradley
Robert J. Collier Jr.
Jeremy S. Mogridge
John A. T. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of AU2002239229A1 publication Critical patent/AU2002239229A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The present invention relates to mammalian anthrax toxin receptor polypeptides and polynucleotides encoding same as well as related polypeptides and polynucleotides, vectors containing the polynucleotides and polypeptides, host cells containing related polynucleotide molecules, and cells displaying no anthrax toxin receptor on an exterior surface of the cells-minus cell lines and animals. The present invention also relates to methods for identifying molecules that bind the anthrax toxin receptor and molecules that reduce the toxicity of anthrax toxin. Finally, the present invention provides methods for treating human and non-human animals suffering from anthrax.
AU2002239229A 2000-12-05 2001-10-03 Receptor for b. anthracis toxin Abandoned AU2002239229A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25148100P 2000-12-05 2000-12-05
US60/251,481 2000-12-05
PCT/US2001/030941 WO2002046228A2 (en) 2000-12-05 2001-10-03 Receptor for b. anthracis toxin

Publications (1)

Publication Number Publication Date
AU2002239229A1 true AU2002239229A1 (en) 2002-06-18

Family

ID=22952145

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002239229A Abandoned AU2002239229A1 (en) 2000-12-05 2001-10-03 Receptor for b. anthracis toxin

Country Status (6)

Country Link
US (4) US7074913B2 (en)
EP (1) EP1395657B1 (en)
AT (1) ATE360071T1 (en)
AU (1) AU2002239229A1 (en)
DE (1) DE60128008T2 (en)
WO (1) WO2002046228A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455673B1 (en) * 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US6808709B1 (en) * 1994-12-30 2004-10-26 The Regents Of The University Of California Immunoglobulins containing protection proteins and their use
JP5008811B2 (en) * 2000-04-28 2012-08-22 プラネット・バイオテクノロジー・インコーポレイテッド Immunoadhesives to prevent rhinovirus infection
US20060015969A1 (en) * 2000-04-28 2006-01-19 Planet Biotechnology, Inc. Novel immunoadhesins for treating and prventing toxicity and pathogen-mediated diseases
US20020168367A1 (en) * 2000-04-28 2002-11-14 Planet Biotechnology Incorporated Novel immunoadhesins for treating and preventing viral and bacterial diseases
US7402660B2 (en) * 2000-08-02 2008-07-22 The Johns Hopkins University Endothelial cell expression patterns
EP1395657B1 (en) * 2000-12-05 2007-04-18 Wisconsin Alumni Research Foundation Receptor for bacillus anthracis toxin
US20070118934A1 (en) * 2001-10-26 2007-05-24 Planet Biotechnology, Inc. Chimeric toxin receptor proteins and chimeric toxin receptor proteins for treatment and prevention of anthrax
US20030144193A1 (en) * 2001-12-20 2003-07-31 Rottman James B. TANGO 197 and TANGO 216 compositions and methods
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
WO2004052277A2 (en) * 2002-12-05 2004-06-24 Wisconsin Alumni Research Foundation Anthrax antitoxins
GB0423974D0 (en) 2004-10-28 2004-12-01 Ares Trading Sa Proteins
US7838252B2 (en) * 2005-02-17 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating a subject having an anthrax toxin mediated condition
ITRM20060337A1 (en) * 2006-06-27 2007-12-28 Biosoot Srl GENE TEM8 (TUMOR ENDOTELIAL MARKER 8) AND ITS FORMS OF EXPRESSION AND DIAGNOSTIC AND THERAPEUTIC USE
US20110117121A1 (en) * 2006-10-27 2011-05-19 James Dao Compositions for treatment and inhibition of pain
TW201425333A (en) * 2007-04-11 2014-07-01 Oncotherapy Science Inc TEM8 peptides and vaccines comprising the same
US7935345B2 (en) 2007-05-21 2011-05-03 Children's Hospital & Research Center At Oakland Monoclonal antibodies that specifically bind to and neutralize bacillus anthracis toxin, compositions, and methods of use
US9181340B2 (en) 2011-06-14 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services TEM8 antibodies, conjugates thereof, and their use
WO2012172495A1 (en) * 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
JP6502931B2 (en) 2013-10-11 2019-04-17 アメリカ合衆国 TEM 8 antibody and use thereof
US10717927B2 (en) 2016-07-14 2020-07-21 Samsung Electronics Co., Ltd. Indium-based quantum dots and production methods thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604201A (en) * 1993-01-08 1997-02-18 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization Methods and reagents for inhibiting furin endoprotease
US5591631A (en) * 1993-02-12 1997-01-07 The United States Of America As Represented By The Department Of Health And Human Services Anthrax toxin fusion proteins, nucleic acid encoding same
US5677274A (en) * 1993-02-12 1997-10-14 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Anthrax toxin fusion proteins and related methods
AU720857B2 (en) * 1995-12-13 2000-06-15 President And Fellows Of Harvard College Use of toxin peptides and/or affinity handles for delivery compounds into cells
US6592872B1 (en) * 1996-09-17 2003-07-15 The United States Of America As Represented By The Department Of Health And Human Services Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein
US7368531B2 (en) * 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US7411051B2 (en) * 1997-03-07 2008-08-12 Human Genome Sciences, Inc. Antibodies to HDPPA04 polypeptide
CA2324379C (en) * 1998-04-01 2012-12-11 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Anthrax lethal factor is a mapk kinase protease
US7175679B2 (en) * 2001-03-29 2007-02-13 Biotempt B.V. Oligopeptide treatment of NF-κB mediated inflammation
WO2000039284A1 (en) * 1998-12-30 2000-07-06 Millennium Pharmaceuticals, Inc. Secreted proteins and nucleic acids encoding them
US6329156B1 (en) * 1999-03-22 2001-12-11 The Regents Of The University Of California Method for screening inhibitors of the toxicity of Bacillus anthracis
JP2003520030A (en) 1999-11-05 2003-07-02 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 28 human secreted proteins
WO2001045639A2 (en) * 1999-12-22 2001-06-28 The Ohio State University Research Foundation Methods for protecting against lethal infection with bacillus anthracis
CA2402563A1 (en) 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
US6569662B1 (en) * 2000-01-21 2003-05-27 Hyseq, Inc. Nucleic acids and polypeptides
CA2747325A1 (en) * 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
AU2001261171A1 (en) * 2000-05-04 2001-11-12 President And Fellows Of Harvard College Compounds and methods for the treatment and prevention of bacterial infection
US7402660B2 (en) * 2000-08-02 2008-07-22 The Johns Hopkins University Endothelial cell expression patterns
EP1395657B1 (en) * 2000-12-05 2007-04-18 Wisconsin Alumni Research Foundation Receptor for bacillus anthracis toxin
US7393932B2 (en) * 2001-04-11 2008-07-01 The Johns Hopkins University Endothelial cell expression patterns
US20060084794A1 (en) * 2001-04-12 2006-04-20 Human Genome Sciences, Inc. Albumin fusion proteins
US20030108556A1 (en) * 2001-06-08 2003-06-12 Mekalanos John J. Therapeutic uses of polyvalent compositions in infectious diseases
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US20070118934A1 (en) * 2001-10-26 2007-05-24 Planet Biotechnology, Inc. Chimeric toxin receptor proteins and chimeric toxin receptor proteins for treatment and prevention of anthrax
GB0126266D0 (en) * 2001-11-01 2002-01-02 Microbiological Res Authority Anthrax antigenic compositions
WO2003050243A2 (en) * 2001-12-10 2003-06-19 Millennium Pharmaceuticals Inc. Novel genes encoding colon cancer antigens
US20040258699A1 (en) * 2002-02-11 2004-12-23 Bowdish Katherine S. Immunotherapeutics for biodefense
WO2004052277A2 (en) * 2002-12-05 2004-06-24 Wisconsin Alumni Research Foundation Anthrax antitoxins
AU2003900747A0 (en) * 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
US7365184B2 (en) * 2003-04-11 2008-04-29 New York University B. anthracis prevention and treatment: mutant B. anthracis lacking luxS activity and furanone inhibition of growth, AI-2 quorum sensing, and toxin production
JP4999158B2 (en) * 2003-05-21 2012-08-15 メダレツクス・インコーポレーテツド Human monoclonal antibody against infection protective antigen of Bacillus anthracis
WO2005081749A2 (en) * 2004-01-23 2005-09-09 Avanir Pharmaceuticals, Inc. Neutralizing human antibodies to anthraxtoxin
US20060246079A1 (en) * 2003-11-14 2006-11-02 Morrow Phillip R Neutralizing human antibodies to anthrax toxin
AU2005251535A1 (en) * 2004-03-03 2005-12-22 Iq Corporation Human anthrax toxin neutralizing monoclonal antibodies and methods of use thereof
US7588912B2 (en) * 2004-10-12 2009-09-15 Regents Of The University Of California Compositions and methods for preventing and treating anthrax diseases

Also Published As

Publication number Publication date
ATE360071T1 (en) 2007-05-15
US20070117159A1 (en) 2007-05-24
US7074913B2 (en) 2006-07-11
DE60128008D1 (en) 2007-05-31
US20060110801A1 (en) 2006-05-25
US20050196407A1 (en) 2005-09-08
EP1395657B1 (en) 2007-04-18
US20060083746A1 (en) 2006-04-20
US7435418B2 (en) 2008-10-14
WO2002046228A3 (en) 2003-12-24
DE60128008T2 (en) 2008-01-10
WO2002046228A2 (en) 2002-06-13
EP1395657A2 (en) 2004-03-10

Similar Documents

Publication Publication Date Title
AU2002239229A1 (en) Receptor for b. anthracis toxin
MXPA02012743A (en) Il-17 molecules and uses thereof.
ATE454463T1 (en) OVEREXPRESSION OF EXTREMOZYM GENES IN PSEUDOMONAS AND CLOSELY RELATED BACTERIA
EP0893496A3 (en) Histidyl tRNA synthetase from Chlamydia trachomatis
WO1996034107A3 (en) Antiviral proteins, dna coding sequences therefor, and uses thereof
EP1553975B8 (en) Optimized fc variants and methods for their generation
WO2003104418A3 (en) Reconstituted polypeptides
NZ323795A (en) Isolated nucleic acid molecules encoding AUR-1 (aurora-1) and AUR-2 polypeptides
MXPA03002413A (en) B7-like molecules and uses thereof.
EP0892060A3 (en) The Chlamydia trachomatis Glutamyl-tRNAGln amidotransferase subunit ratA
DK1005540T3 (en) IKK-beta proteins, nucleic acids and methods
AU8881201A (en) Tnf receptor-like molecules and uses thereof
WO2003104425A3 (en) Novel stable anti-cd22 antibodies
WO2001068705A3 (en) Il-17 receptor like molecules and uses thereof
MX2007005520A (en) Polypeptides having antimicrobial activity and polynucleotides encoding same.
NZ504669A (en) Virulence-associated nucleic acid sequences and uses in identification of anti-virulence agents
WO2000073509A3 (en) Molecules for diagnostics and therapeutics
WO2000005374A3 (en) Molecules associated with cell proliferation
MXPA03010728A (en) B7 related protein-2 molecules and uses thereof.
PL374550A1 (en) Il-17 like molecules and uses thereof
WO2001066752A3 (en) Reproduction-specific genes
WO2001042285A3 (en) Extracellular matrix and cell adhesion proteins as well as genes encoding them
WO2001074903A3 (en) Cd20/ige-receptor like molecules and uses thereof
WO2005051985A3 (en) Methods for purifying pertussis toxin and peptides useful therefor
WO2002020756A3 (en) Secretory molecules